Ask AI
HER2 Targeted ADCs Clinical Data

CME

Evaluating Clinical Data With HER2-Targeted ADCs in Genitourinary, Gastrointestinal, and Gynecologic Malignancies

Physicians: Maximum of 0.25 AMA PRA Category 1 Credit

Released: August 29, 2025

Expiration: February 28, 2026

Activity

Progress
1 2
Course Completed

References

  1. Wang R, et al. Antibody-drug conjugates (ADCs): current and future biopharmaceuticals. J Hematol Oncol. 2025;18:51.
  2. Arthur G, et al. Pharmacology and pharmacokinetics of antibody-drug conjugates, where do we stand? Cancer Treat Rev. 2025;135:102922.
  3. Meric-Bernstam F, et al. Efficacy and safety of trastuzumab deruxtecan in patients with HER2-expressing solid tumors: Primary results from the DESTINY-PanTumor02 phase II trial. J Clin Oncol. 2024;42:47-58.
  4. Li BT, et al. Trastuzumab deruxtecan in patients with solid tumours harbouring specific activating HER2 mutations (DESTINY-PanTumor01): an international, phase 2 study. Lancet Oncol. 2024;25:707-719.
  5. Plotkin A, et al. Implementation of HER2 testing in endometrial cancer, a summary of real-world initial experience in a large tertiary cancer center. Cancers. 2024;16:2100.
  6. Lee D, et al. HER2 expression in ovarian cancer: Its relationship with HRD status, and other biomarkers. Presented at: European Society for Medical Oncology Gynaecological Cancers Congress; March 7-10, 2024. Abstract 765P.
  7. Meric-Bernstam F, et al. Efficacy and safety of trastuzumab deruxtecan (T-DXD) in patients (PTS) with HER2-expressing solid tumors: Destiny-PANTUMOR02 (DP-02) interim results. J Clin Oncol. 2023;41:10.
  8. Lee EK, et al. Diagnostic and therapeutic advances for HER2-expressing or amplified gynecologic cancers. Gynecol Oncol. 2025;195:152-164.
  9. National Comprehensive Cancer Network. NCCN guidelines: ovarian cancer/fallopian tube cancer/primary peritoneal cancer. Version 3.2025. nccn.org. Accessed August 25, 2025.
  10. National Comprehensive Cancer Network. NCCN guidelines: cervical cancer. Version 4.2025. nccn.org. Accessed August 25, 2025.
  11. National Comprehensive Cancer Network. NCCN guidelines: uterine neoplasms. Version 3.2025. nccn.org. Accessed August 25, 2025.
  12. Scherrer E, et al. HER2 expression in urothelial carcinoma, a systematic literature review. Front Oncol. 2022;12:1011885.
  13. Zhou L, et al.1979P Disitamab vedotin (DV) plus toripalimab (T) in unresectable locally advanced or metastatic urothelial carcinoma (la/mUC): Long-term outcomes from a phase Ib/II study. Ann Oncol. 2024;35:S1145.
  14. Ehrlich MI, et al. Novel strategies and therapeutic advances for bladder cancer. Cancers (Basel). 2025;17:2070.
  15. Sheng X, et al. Neoadjuvant treatment with disitamab vedotin plus perioperative toripalimab in patients with muscle-invasive bladder cancer (MIBC) with HER2 expression: Updated efficacy and safety results from the phase II RC48-C017 trial. J Clin Oncol. 2025;43:665-665.
  16. National Comprehensive Cancer Network. NCCN guidelines: Bladder Cancer. Version 1.2025. nccn.org. Accessed August 25, 2025.
  17. Ayasun R, et al. The role of HER2 status in the biliary tract cancers. Cancers. 2023;15:2628.
  18. Kanwal P, et al. Trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-overexpressing/amplified (HER2+) metastatic colorectal cancer (mCRC): Primary results from the multicenter, randomized, phase 2 DESTINY-CRC02 study. J Clin Oncol. 2023;41:3501.
  19. US Food and Drug Administration. FDA grants accelerated approval to fam-trastuzumab deruxtecan-nxki for unresectable or metastatic HER2-positive solid tumors. fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-fam-trastuzumab-deruxtecan-nxki-unresectable-or-metastatic-her2. Accessed August 25, 2025.
  20. Sartore-Bianchi A, et al. Pertuzumab and trastuzumab emtansine in patients with HER2-amplified metastatic colorectal cancer: the phase II HERACLES-B trial. ESMO Open. 2020;5:e000911.
  21. Siena S, et al. HER2-related biomarkers predict clinical outcomes with trastuzumab deruxtecan treatment in patients with HER2-expressing metastatic colorectal cancer: biomarker analyses of DESTINY-CRC01. Nat Commun. 2024;15:10213.
  22. Yoshino T, et al; DESTINY-CRC01 Investigators. Final results of DESTINY-CRC01 investigating trastuzumab deruxtecan in patients with HER2-expressing metastatic colorectal cancer. Nat Commun. 2023;14:3332.
  23. National Comprehensive Cancer Network. NCCN guidelines: colon cancer. Version 4.2025. nccn.org. Accessed August 25, 2025.
  24. Yamaguchi K, et al. Trastuzumab deruxtecan in anti–human epidermal growth factor receptor 2 treatment–naive patients with human epidermal growth factor receptor 2–low gastric or gastroesophageal junction adenocarcinoma: Exploratory cohort results in a phase II trial. J Clin Oncol. 2022;41;816-825.
  25. Van Cutsem E, et al. Trastuzumab deruxtecan in patients in the USA and Europe with HER2-positive advanced gastric or gastroesophageal junction cancer with disease progression on or after a trastuzumab-containing regimen (DESTINY-Gastric02): primary and updated analyses from a single-arm, phase 2 study. Lancet Oncol. 2023;24:744.
  26. Shitara K, et al. Trastuzumab deruxtecan (T-DXd) vs ramucirumab (RAM) + paclitaxel (PTX) in second-line treatment of patients (pts) with human epidermal growth factor receptor 2-positive (HER2+) unresectable/metastatic gastric cancer (GC) or gastroesophageal junction adenocarcinoma (GEJA): Primary analysis of the randomized, phase 3 DESTINY-Gastric04 study. J Clin Oncol. 2025;43:LBA4002.
  27. Modi S, et al. Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer: a plain language summary of the DESTINY-Breast04 study. Future Oncol. 2025;21:367-380.
  28. Ximena BN, et al. HER2-low across solid tumours: different incidences and definitions, Pathology, 2025;57:403.